A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With Asthma

NCT ID: NCT06795906

Last Updated: 2025-10-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-01-28
• Study Completion Date: 2025-06-27

Brief Summary

This is a randomised, placebo-controlled, double-blinded, sponsor-unblinded study to assess the safety, pharmacokinetic (PK), and pharmacodynamic (PD) effect of AZD8630 in adult participants with asthma on medium-to-high dose inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA).

Detailed Description

The purpose of this study is to assess the safety, PK, and PD of AZD8630 compared to placebo in participants with asthma and elevated fractional exhaled nitric oxide (FeNO) on a combination of medium-to-high dose ICS and LABA medications.

The study will comprise of:

• A Screening/Enrollment Period of up to 14 to 28 days before dosing.
• A Treatment Period/End of Treatment Visit. On Day 1, participants will be randomised to AZD8630 or corresponding placebo. Study intervention will be self-administered once daily up to Day 14. Participants will return to the study site for clinical and safety assessments on Day 7 and clinical and safety assessments and PK sampling on Day 14.
• A Follow-up Visit 1 week after last dose.

Conditions

Asthma

Study Design

• Allocation Method: NA
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

AZD8630 Dose A

Participants will self-administer AZD8630 Dose A daily from Day 1 up to Day 14.

Group Type: EXPERIMENTAL

AZD8630

Intervention Type: DRUG

AZD8630 will be administered via dry powder inhalation (DPI).

Saphira device

Intervention Type: DEVICE

AZD8630 or placebo will be administered to participants via Saphira device.

Placebo

Participants will self-administer corresponding placebo daily from Day 1 up to Day 14.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo will be administered via DPI.

Saphira device

Intervention Type: DEVICE

AZD8630 or placebo will be administered to participants via Saphira device.

Interventions

AZD8630

AZD8630 will be administered via dry powder inhalation (DPI).

Intervention Type: DRUG

Placebo

Placebo will be administered via DPI.

Intervention Type: OTHER

Saphira device

AZD8630 or placebo will be administered to participants via Saphira device.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1 Participants who have documented physician-diagnosis of asthma for at least 12 months, as evidenced by any of the following:

1. Post-bronchodilator (BD) reversibility of FEV1 ≥ 12% and ≥ 200 milliliters (mL) within 5 years prior to Visit 1, at Visit 1 or

2. Peak expiratory flow (PEF) average daily variability > 10% over a 2-week period within 5 years prior to Visit 1, or

3. Variability of FEV1 > 12% and 200 mL between any 2 clinical visits within 5 years prior to Visit 1, or

4. Positive bronchial challenge test within 5 years prior to Visit 1. A positive test is defined as a fall in FEV1 from pre-challenge of ≥ 20% with standard doses of methacholine or ≥ 5% with standardised hyperventilation, hypertonic saline, or mannitol challenge, or

5. Positive exercise challenge test within 5 years prior to Visit 1. A positive test is defined as a fall in FEV1 of > 10% and > 200 mL from pre-challenge, or

6. Significant increase in lung function after 4 weeks of Inhaled Corticosteroids (ICS) anti-inflammatory treatment within 5 years prior to Visit 1, defined as an increase in FEV1 > 12% and 200 mL (or PEF by > 20%).

3 Treated with medium or high dose ICS (as per GINA 2023) in combination with long-acting beta-agonists (LABA) (GINA step 4 or 5 therapy); the dose of ICS must be stable for at least 30 days prior to Visit 1. The ICS can be contained within an ICS-LABA fixed-dose combination product.

• Treatment with additional asthma controller therapies (eg, long-acting muscarinic-agonists) at a stable dose ≥ 30 days prior to Visit 1 is allowed.

4 Asthma Control Questionnaire-6 (ACQ-6) score in the range 0.75-3 at both screening and randomisation.

5 Pre-bronchodilator FEV1 ≥ 40%. 6 FeNO ≥ 30 parts per billion (ppb) at both screening and randomisation. 7 At least 70% compliance with usual asthma background medication during the screening period (14 days prior to randomisation) based on the daily asthma ePROs. At least 70% compliance with electronically recorded participant reported outcomes (ePRO) device completion during the screening period (14 days prior to randomisation). This is defined as completing the ePRO any 10 mornings and 10 evenings in the last 14 days prior to randomisation.

8 Minimum 70% compliance with PEF measurements during the screening period (14 days prior to randomisation). This is defined as performing PEF for any 10 mornings and any 10 evenings in the last 14 days prior to randomisation.

9 Body mass index (BMI) within the range 18 to 35 kilograms per meter (kg/m2) inclusive and weight at least 45 kg at the time of signing the informed consent.

Exclusion Criteria

1. Life-threatening asthma defined as a history of significant asthma episode(s) involving intubation, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s).

2. Completed treatment for respiratory infection and/or asthma exacerbation with systemic corticosteroids and/or antibiotics in the 4 weeks prior to Visit 1 or during the screening period.

3. Clinically important pulmonary disease other than asthma; including but not limited to participants with co-existent chronic obstructive pulmonary disease (COPD).

4. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:

1. Affect the safety of the participant throughout the study.

2. Influence the findings of the study or the interpretation.

3. Impede the participant's ability to complete the entire study.

5. Participants who, in the opinion of the investigator, have evidence of active tuberculosis (TB) or are currently on treatment for active or latent TB. Investigation for active or latent TB with interferon gamma release assay (IGRA) and/or chest X-ray should only be considered if deemed clinically indicated by the Principal Investigator.

6. Medical history of or treatment for hepatitis B or hepatitis C, except for cured hepatitis C, as defined by:

1. Positive test for hepatitis B surface antigen (HBsAg).

2. Positive test for anti- hepatitis B core antibody (HBc Ab): Participants who test positive for anti-HBc Ab but negative for HBsAg may be enrolled if their hepatitis B virus (HBV) DNA test result is negative.

3. Positive test for anti-hepatitis C antibody: Participants who test positive for anti-hepatitis C antibody may be enrolled if their hepatitis C viral ribonucleic acid (RNA) test result is negative in the absence of cirrhosis.

7. Participants with known human immunodeficiency virus (HIV) or with a positive HIV test at screening.

8. Any other clinically relevant abnormal findings in laboratory testing including haematology and clinical chemistry, on vital signs, electrocardiogram (ECG), or physical examination between consent and randomisation, that in the opinion of the investigator or medical monitor, might compromise the safety of the participant in the study or interfere with evaluation of the study intervention. Abnormal findings include, but are not limited to:

1. Alanine aminotransferase/transaminase (ALT) or aspartate aminotransferase/transaminase AST > 2 × upper limit of normal (ULN).

2. Total bilirubin (TBL) > 1.5 × ULN (unless due to Gilbert's disease).

3. Evidence of chronic liver disease.

9. Congenital long QT syndrome or prolonged QT corrected for heart rate by Fridericia (QTcF) > 470 ms or history of QT prolongation associated with other medications that required discontinuation of that medication.

10. Current untreated or uncontrolled arrhythmia (eg, multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia). Note: Participants with clinically significant sinus nodal disease/bradycardia or Type 2 second- or third-degree atrioventricular (AV) block can be included if treated with pacemaker.

11. Participants with recent (within 3 months of Visit 1) myocardial infarction, unstable angina pectoris, stroke, percutaneous coronary intervention and coronary artery bypass grafting (within 6 months of Visit 1).

12. Current smokers, former smokers with > 10 pack-years history, or former smokers who stopped smoking < 6 months before Visit 1 (including all forms of tobacco, e-cigarettes (vaping), and other recreational drugs including marijuana).

13. History of current or previous alcohol or drug misuse in the 12 months prior to screening. The use of oral cannabis is permitted.

14. Current diagnosis of cancer or unresectable cancer that has not been in complete remission for at least 5 years prior to Visit 1. Note: Squamous cell and basal cell carcinomas of the skin and cervical carcinoma-in-situ that have been treated and considered cured at the time of enrolment are not exclusionary.

15. History of documented immune complex disease (Type III hypersensitivity reactions) to monoclonal antibody (mAb) administration.

16. History of hypersensitivity or anaphylaxis to any components of AZD8630 formulation.

17. History of anaphylaxis or ongoing clinically important serious allergy, as judged by the investigator, or history of anaphylaxis that required the use of epinephrine/adrenaline or hospitalisation.

18. A helminth parasitic infection diagnosed within 24 weeks of screening that has not been treated or has not responded to standard of care therapy.

19. Use of the following medicines within the specified time before screening:

1. Treatment with marketed or investigational biologics for asthma or immunological disease within 4 months or a minimum of 5 half-lives, whichever is longer, prior to the screening visit.

2. Systemic steroids within 4 weeks prior to the screening visit. Note: Intranasal steroid use is permitted, provided that there has been a stable treatment regimen for 4 weeks.

3. Live, attenuated, or mRNA vaccine in the 4 weeks prior to screening visit.

4. Any systemic immunosuppressive therapy within 3 months of screening visit until the end of the follow-up period.

5. Use of allergen immunotherapy within 3 months of screening visit, except for stable maintenance dose allergen-specific immunotherapy started 4 weeks prior to screening visit.

6. Bronchial thermoplasty in the last 12 months prior to screening visit.

7. Receipt of immunoglobulin or blood products within 4 weeks prior to screening visit.

20. Participation in another clinical study with a study intervention administered within 5 half-lives or in accordance with local regulations (whichever is longer) prior to screening.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Parexel

INDUSTRY

Sponsor Role: collaborator

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Research Site

Ahrensburg, , Germany

Research Site

Berlin, , Germany

Research Site

Mainz, , Germany

Countries

Germany

Other Identifiers

D6830C00004

Identifier Type: -

Identifier Source: org_study_id